论文部分内容阅读
非霍奇金淋巴瘤 (ｎｏｎ Ｈｏｄｇｋｉｎｌｙｍｐｈｏｍａ ,ＮＨＬ) ,是放、化疗敏感性肿瘤 ,其中约 10 %～ 2 5 %侵袭性 (中、高度恶性 )患者属于原发性难治病例 ,另外初治达ＣＲ病例中约 30 %于 2～ 3年内复发。复发及难治性侵袭性淋巴瘤患者需给予二线挽救化疗。二线挽救化
Non Hodgkin lymphoma (NHL) is a radiotherapy-chemosensitive tumor. About 10% to 25% of the patients with invasive (medium or high-grade) malignancy belong to primary refractory cases. In addition, Approximately 30% of CR cases relapse within 2 to 3 years. Patients with recurrent and refractory aggressive lymphoma should receive second-line salvage chemotherapy. Second-line saving